- Paper Report
- Open Access
Epifibatide is justified in community hospital treatment of ACS
- Joanna Lyford1
© Biomed Central Ltd 2001
- Received: 14 March 2001
- Published: 18 October 2001
- Asprin, glycoprotein IIa/IIIb, unstable angina
The study aims to show that the use of glycoprotein (GP) IIb/IIIa antagonist epifibatide in patients with acute coronary syndromes (ACS) admitted to community hospitals reduces the need for transfer and improved clinical outcomes.
Results showed that epifibatide reduced the need for transfer in comparison with placebo, with 16% transferred versus 20%. The GP IIb/IIIa antagonist also improved clinical outcomes, with a 2.5% reduction in 30-day incidence of death or MI independent of transfer status. There was also a 5.5% reduction in transferred patients.
Data on 429 patients at 153 sites from the Platelet glycoprotein IIb/ IIIa in Unstable Angina; Receptor Suppression Using Integrilin Therapy (PURSUIT) trial who were admitted to community hospitals and transferred during study drug infusion ('transfer patients') were compared with 1987 patients who either remained at the hospital or were transferred after study-drug termination ('nontransfer patients').
- Greenbaum AB, Harrington RA, Hudson MP, MacAulay CM, Wilcox RG, Simoons ML, Berdan LG, Guerci A, Cokkinos DV, Kitt MM, Lincoff AM, Topol EJ, Califf RM, Ohman EM, for the PURSUIT Investigators : Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol. 2001, 37: 492-498.View ArticlePubMedGoogle Scholar